Ambrisentan for in pediatric pulmonary arterial hypertension: A cost‐utility analysis

Abstract

AbstractIntroductionDespite the growing evidence of efficacy, little is known regarding the efficiency of ambrisentan to decrease cost and improve the functional classes of pediatric patients with pulmonary arterial hypertension. This study aims to determine the cost‐utility of ambrisentan regarding sildenafil to treat pediatric patients with pulmonary arterial hypertension in Colombia.MethodsA decision tree model was used to estimate the cost and quality‐adjusted life‐years (QALYs) of ambrisentan, or sildenafil in pediatric patients with pulmonary arterial hypertension. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost‐effectiveness was evaluated at a willingness‐to‐pay (WTP) value of US$5180.ResultsThe base‐case analysis showed that compared with sildenafil, ambrisentan was associated with higher costs and higher QALYs. The expected annual cost per patient with ambrisentan was US$16,105 and with sildenafil was US$1431. The QALYs per person estimated with ambrisentan was 0.40 and for sildenafil was 0.39. The estimated improvement in quality of life and reduced costs results in an estimate of economic dominance for sildenafil over ambrisentan.ConclusionOur economic evaluation shows that ambrisentan is not cost‐effective regarding sildenafil to treat pediatric patients with pulmonary arterial hypertension in Colombia. Our study provides evidence that should be used by decision‐makers to improve clinical practice guidelines.